GenVec Inc  

(Public, NASDAQ:GNVC)   Watch this stock  
Find more results for GNVC
0.493
-0.024 (-4.66%)
Sep 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.49 - 0.53
52 week 0.35 - 3.69
Open 0.50
Vol / Avg. 30,566.00/143,942.00
Mkt cap 11.45M
P/E     -
Div/yield     -
EPS -0.35
Shares 22.74M
Beta 2.22
Inst. own 27%
Nov 7, 2016
Q3 2016 GenVec Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 5, 2016
Q2 2016 GenVec Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -4596.15% -739.55%
Operating margin -6592.31% -742.03%
EBITD margin - -731.07%
Return on average assets -52.75% -52.21%
Return on average equity -73.10% -62.40%
Employees 15 -
CDP Score - -

Address

910 Clopper Rd Ste 220n
GAITHERSBURG, MD 20878-1353
United States - Map
+1-240-6320740 (Phone)
+1-240-6320735 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Officers and directors

Wayne T. Hockmeyer Ph.D. Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Douglas J. Swirsky President, Chief Executive Officer, Corporate Secretary, Director
Age: 45
Bio & Compensation  - Reuters
James V. Lambert Chief Financial Officer, Chief Accounting Officer, Senior Director, Controller, Treasurer
Age: 50
Bio & Compensation  - Reuters
Bryan T. Butman Ph.D. Senior Vice President - Development
Age: 62
Bio & Compensation  - Reuters
Douglas E. Brough Ph.D. Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Stefan D. Loren Ph.D. Director
Age: 51
Bio & Compensation  - Reuters
Quinterol J. Mallette M.D. Director
Age: 41
Bio & Compensation  - Reuters
Michael S. Richman Director
Age: 54
Bio & Compensation  - Reuters
William N. Kelley M.D. Independent Director
Age: 75
Bio & Compensation  - Reuters
Marc R. Schneebaum Independent Director
Age: 60
Bio & Compensation  - Reuters